Soluble Fas (sFas) in the serum is believed to be able to inhibit apoptosis of lymphocytes. It has been reported that the serum sFas level is increased in various diseases, including malignant lymphoma and systemic lupus erythematosus. We studied the association between sFas and the prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL). Compared with normal controls, the serum sFas level was increased significantly in patients with aggressive NHL and adult T cell leukemia/lymphoma. Among patients with aggressive NHL, the complete remission rate was significantly decreased in the subgroup having high serum sFas levels. Both the overall survival rate and the disease-free survival (DFS) rate were significantly lower for this subgroup than for patients with low serum sFas levels. The 5-year survival rates estimated by the KaplanMeier method for patients with high and low serum sFas levels were 27.6% and 68.3%, respectively (P ‫؍‬ 0.0001). The 5-year DFS rates estimated for patients with high and low serum sFas levels were 44.7% and 71.9%, respectively (log-rank test: P ‫؍‬ 0.0023, and generalized Wilcoxon test: P ‫؍‬ 0.0014). Among patients with a low and low-intermediate risk group according to the International Prognostic Index (IPI), the 5-year survival rates for low and high serum sFas subgroups were 72.8% and 42.0%, respectively, showing a significant difference (Wilcoxon test: P ‫؍‬ 0.0163, log-rank test: P ‫؍‬ 0.0115). Among patients with a high-intermediate and high risk group, the 5-year survival rates for low and high serum sFas subgroups were 51.6% and 17.4%, respectively, again showing a significant difference (Wilcoxon test: P ‫؍‬ 0.0001, log-rank test: P ‫؍‬ 0.0002). Multivariate analysis of a series of prognostic factors, including the five used to calculate the IPI, showed that the serum sFas level was an independent prognostic factor for the overall survival. Based on these results, a serum sFas level of 10 ng/ml or more can be considered to indicate a poor prognosis in patients with advanced NHL, and this finding may be useful for developing strategies for further treatment.
Introduction
The cell-surface protein Fas/APO-1 is a member of the nerve growth factor (NGF)/tumor necrosis factor (TNF) receptor superfamily. Fas/APO-1 is expressed by a variety of human B and T cell lines, as well as well as by many different tumor cells and various normal human tissues. Fas/APO-1 is a particularly important receptor, since its triggering by antibodies or Fas-ligand may cause apoptosis in susceptible cells. [1] [2] [3] [4] Soluble isoforms of the Fas molecule (sFas) have been identified 5 and Cheng et al 5 have reported an increased serum concentration of sFas in patients with systemic lupus erythematosus (SLE). The sFas molecule is considered to inhibit apoptosis of lymphocytes, and it has been reported that its serum level is elevated in patients with malignant lymphoma and lymphocytic leukemia. 6 In recent years, treatment for non-Hodgkin's lymphoma Correspondence: N Niitsu: Fax: 03-3763-8298 Received 9 March 1999; accepted 25 May 1999 (NHL), particularly intermediate-and high-grade NHL, has been chosen depending on the level of risk as defined by the International Prognostic Index (IPI), calculation of which is based on five independent prognostic factors (age, performance status (PS), number of extranodal lesions, Ann Arbor stage, and serum lactate dehydrogenase level). 7 Standard therapy, in which the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen plays a central role, is indicated for patients having an index of 0 or 1 (the low (L) risk group) and an index of 2 (the low-intermediate (L-I) risk group). For patients in the high-intermediate (H-l) and high (H) risk groups, who have three or more of the five IPI risk factors, high-dose chemotherapy is administered in combination with peripheral blood stem cell transplantation. Even if NHL is treated in accordance with these criteria, however, therapy is not effective for some patients in the L and L-I risk groups, but is effective for some patients in the H-l and H risk groups. Consequently, it is doubtful whether all of the patients in the H-l and H risk groups require such high-dose chemotherapy.
In the present study, we determined serum sFas levels in all patients with aggressive NHL, and the association with various outcomes was investigated. We found that a high serum sFas level is related to a poor prognosis, particularly in the H-l and H risk groups.
Materials and methods

Patients
sFas was measured in 175 consecutive untreated patients who were managed at the 1st Department of Internal Medicine, Toho University School of Medicine (Tokyo, Japan) from 1987 to 1996. Of the 175 patients, 158 had NHL. Twenty-seven patients had indolent type, 131 had aggressive lymphoma according to the REAL schema. 8 Indolent lymphoma was of the B cell lineage in all patients, including two with lymphoplasmacytic lymphoma, two with splenic marginal zone lymphoma, seven with marginal zone B cell lymphoma, and 16 with follicle center lymphoma (grade I/II). Aggressive lymphoma was of the B cell lineage in 99 patients and of the T cell lineage in 32. The aggressive B cell lymphoma was mantle cell lymphoma in six patients, follicle center lymphoma (grade III) in 18, and diffuse large B cell lymphoma in 75. Aggressive T cell type was peripheral T cell lymphoma in 25 patients, angioimmunoblastic lymphoma (AIL) in two, angiocentric lymphoma in one, and anaplastic large cell (T and null cell types) in four (two were ALK-positive and two were ALK-negative). Among patients with aggressive and highly aggressive lymphoma, those receiving COP-BLAM therapy were scheduled to be included in this study, but no patient with highly aggressive lymphoma was actually enrolled.
In addition, nine patients had Hodgkin's disease and eight others had adult T cell leukemia/lymphoma (ATLL), excluding the lymphoma type of disease. The median age was 64 years (range: 18-80 years). Clinical staging was performed according to the Ann Arbor classification system. 9 Evaluation included a complete history and physical examination: chest roentgenography; bone marrow aspiration and biopsy; computed tomography of the chest, abdomen and pelvis; hemogram and differential counts; and routine biochemistry tests. Laparotomy was not performed for staging. According to the IPI, the risk was L in 34, L-l in 55, H-l in 30, and H in 12 patients. The 175 patients were treated with combination chemotherapy. Patients with aggressive lymphoma and disseminated disease were usually treated with COP-BLAM 10 (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine), or biweekly COP-BLAM with granulocyte colony-stimulating factor (G-CSF).
11 Indolent lymphoma was treated with COP (cyclophosphamide, vincristine, prednisone) or COP-BLAM regimen. All patients were followed-up at intervals of a few months. Re-evaluation included physical examination, hemogram and differential counts, biochemistry tests, and computed tomography of the chest, abdomen and pelvis. The median follow-up time was 66 months (range: 23-122 months). Of the 131 patients with aggressive NHL, 99 are still alive after follow-up for 88-120 months (median: 68 months). The other 32 patients died between 1 and 34 months (median: 12 months) after diagnosis.
Plasma samples were obtained from 34 healthy volunteers with a mean age of 62 years (range: 19-84 years) for comparison. Samples were collected if the controls had not had fever within 1 week, were not receiving any medication, were not known to be pregnant, and did not have a history of any chronic or acute illnesses.
Enzyme-linked immunosorbent assay (ELISA) for sFas
A sandwich enzyme immunoassay (sFas ELISA kit; MBL, Nagoya, Japan) was used to determine the serum sFas level. Briefly, 10 l of serum was incubated with a biotin-labeled monoclonal antibody against sFas for 2 h in precoated microwells. After washing, streptavidin-horseradish peroxidase was added for 1 h and development was done with TMB substrate solution. The reaction was then stopped and the absorbance determined at 450 nm. The sFas level (g/ml) was calculated from a standard curve. Data are shown as the mean values of triplicate samples.
Soluble interleukin-2 receptor (sIL-2R) levels were also measured with a sandwich ELISA, as described elsewhere. 12 
Statistical analysis
The response to treatment was documented on completion of chemotherapy. Complete remission (CR) was defined as the absence of detectable disease based on clinical, radiologic and histologic criteria. Partial remission (PR) required a Ͼ50% reduction of tumor volume. The duration of CR was calculated from the completion of chemotherapy to relapse or last follow-up. Overall survival (OS) was the interval from initiation of therapy to the time of death or last follow-up. Survival analysis was performed according to the Kaplan-Meier method. 13 Disease-free survival (DFS) was defined as the absence of any recurrence, so patients who never reached CR had a DFS of 0 months. The statistical significance of differences in survival was determined by the log-rank and generalized Wilcoxon's tests.
14 Differences between groups were evaluated by the Mann-Whitney's U test (nonparametric analysis), 15 and P Ͻ 0.05 was taken to indicate significance. Multivariate analysis of the prognosis was performed using Cox's proportional-hazards regression model. 16 All calculations were performed with SAS software (version 6.10; SAS Institute, Cary, NC, USA).
Results
Serum sFas level in patients and healthy controls
The mean (± s.d.) serum sFas level of the healthy controls was 1.88 ± 0.87 ng/ml. The mean level for the patients with aggressive NHL and ATLL was 7.73 ± 6.20 ng/ml (P = 0.00001) and 14.29 ± 3.24 ng/ml (P = 0.00001), respectively, and these levels were higher than the control value. The mean sFas level for patients with Hodgkin's disease and indolent NHL was 4.74 ± 1.73 ng/ml and 5.67 ± 3.91 ng/ml, respectively, and these levels were not significantly different from the control value ( Figure 1 ). Serum sFas levels were significantly correlated with serum LDH levels (Y = 6.722 + 0.0014X, r = 0.2943, P = 0.00065) and sIL-2R levels (Y = 6.642 + 0.0001X, r = 0.3664, P = 0.000017) (Figure 2 ). Table 1 shows the clinical characteristics of the 131 patients with aggressive NHL. An elevated serum sFas level before treatment was correlated with poor prognostic features, such as a poor performance status, an elevated LDH levels, Ann Arbor stage III or IV, H-l and H risk groups (IPI), and an elevated serum (sIL-2R) levels (P р 0.01 for all comparisons, Mann-Whitney U test) ( Table 1) .
sFas and the clinical characteristics of aggressive NHL (Table 1)
CR was achieved in 110 (84%) of the 131 patients. These 110 patients had an sFas level of 6.73 ± 5.17 ng/ml at diagnosis, which was significantly lower than the mean level (12.99 ± 8.35 ng/ml) of those who showed a partial response or failed to respond (P = 0.003). There was no correlation between the serum sFas level and any histologic type in the REAL, nor was there any difference of the serum sFas level between T cell and B cell NHL.
Assessment of the correlation of sFas with overall survival and DFS in aggressive NHL
The 131 patients with aggressive NHL were divided into groups having different sFas levels at a cut-off value of 10 ng/ml. Both overall and DFS rates were calculated for patients falling into each 1 ng/ml interval from an sFas concentration of 3 ng/ml upward. Both rates were significantly different for patients having sFas levels higher than 10 ng/ml from those for patients with levels of 10 ng/ml or less. Consequently, an sFas concentration of 10 ng/ml was taken as the cut-off value.
The 5-year survival rates for the high and low sFas groups were 27.6% and 68.3%, respectively (P = 0.0001 for both logrank test and generalized Wilcoxon test), with DFS being 44.7% and 71.9% (log-rank test: P = 0.0023, and generalized Wilcoxon test: P = 0.0014) (Figures 3a, 4a ). Patients were next divided into two groups by the IPI score (L plus L-I and H-I plus H risk groups), and overall survival and DFS were calculated based on the sFas level in each group.
Among patients who were from the L + L-I risk groups according to the IPI, the 5-year survival rates for the low and high serum sFas level subgroups were 72.8% and 42.0%, respectively, and the difference was significant (Wilcoxon test: P = 0.0163, log-rank test: P = 0.0115) (Figure 3b) . Similarly, among patients from the H-I + H risk group, the 5-year sur- vival rates for the low and high serum sFas level subgroups were 51.6% and 17.4%, respectively (Wilcoxon test: P = 0.0001, log-rank test: P = 0.0002), again showing a significant difference (Figure 3c ). Among patients from the L + L-I risk group, the 5-year DFS rates for the low and high serum sFas level subgroups were 74.6% and 54.7%, respectively, without any significant difference (Figure 4b ). Among patients from the H-I + H risk group, however, the 5-year DFS rate for the low serum sFas level subgroup was 60.8%, which was significantly higher than that of the high serum sFas level subgroup (33.3%) (Wilcoxon test: P = 0.0156 log-rank test: P = 0.0282) (Figure 4c ).
Univariate and multivariate analyses of overall and DFS in patients with aggressive NHL
The overall survival was significantly worse for patients who were 60 years or older and had a WHO PS of 2ෂ4, a serum LDH level that was normal or raised, belonged to the IPI H-I + H risk group, had T cell NHL, had an sIL-2R of 1000 U/ml or higher, and had a serum sFas level of 10 ng/ml or higher. The DFS rate was significantly lower in patients with a PS of 2-4, normal or raised serum LDH levels, T cell NHL, and an sFas level of 10 ng/ml or higher (Table 2 ). Multivariate analysis of serum sFas and the five factors used to calculate the IPI was performed with the Cox proportional hazards regression model and showed that the Fas level was an independent prognostic factor for both overall survival and DFS (Table 3) .
Discussion
Fas antigen is a member of the TNF receptor superfamily, and can induce apoptosis in cells after binding by its natural ligand ( acute myelogenous leukemia, 17 B and T cell leukemia, and lymphoma. 6 The sFas level was reported to be increased in AML with active disease, and was not associated with any other laboratory parameter. In AML, accordingly, sFas may be secreted or shed by reactive or stromal cells rather than being produced by leukemic cells. 17 Among NHL patients, elevation of serum sFas has been reported in centroblastic and centrocytic B cell lymphoma, 6 but was not correlated with the karyotype or with the level of anti-apoptotic bcl-2 protein. NHL is considered to be resistant to chemotherapy when the serum sFas level is high. Kondo et al 18 have reported that both bcl-2 and an apoptosis-inducing receptor (CD95) are expressed by many low-grade lymphomas. Overexpression of bcl-2 is considered to be a prog- The present study demonstrated that the serum sFas level was higher in patients with aggressive NHL and ATLL than in healthy controls. In aggressive NHL, the sFas level varied widely, ranging from 1 to 32.25 ng/ml (mean ± s.d.: 7.73 ± 6.2 ng/ml). Thus, sFas remained within the normal range in some patients and was elevated in others. In ATLL, in contrast, the sFas level ranged from 8.6 to 18.1 ng/ml (mean ± s.d.: 14.29 ± 3.24 ng/ml) and was elevated in all patients. Kamihira et al 20 studied serum sFas levels in human retroviral infection and diseases associated with such infection, and they reported that the level in carriers of human T cell leukemia virus type-I (HTLV-I) was comparable to that in healthy controls, but sFas level was elevated in patients with ATL and AIDS (P Ͻ 0.01). These findings are consistent with our data. All patients with ATLL died within 2 years. Recently, it has been reported that sFas was increased in angioimmunoblastic T cell lymphoma (AIL). 21 The serum sFas levels of two patients with AIL included in the present study were 10.2 and 14.6 ng/ml (data not shown). In addition, it has been reported that the serum sFas level was higher in men than in women, and that it increased with age. In our patients with aggressive NHL, however, the sFas level did not depend on either age or sex, 22 but there was a significant correlation between serum sFas and sIL-2R levels. These two receptors are probably produced by T cells and by lymphoma cells that have undergone the same activation process.
In recent years, various prognostic factors for NHL have been studied. The IPI is a typical one. In addition, serum cytokines such as soluble IL-2R, 12 IL-6 23 and IL-10, 24 and adhesion molecules have been studied. Soluble ICAM-1 25 has been reported to be related to the tumor burden and disease activity, whereas soluble CD44 26 is associated with the prog-nosis of diffuse large cell lymphoma. Mutations of the p53 gene have been shown to be associated with a poor prognosis of aggressive B cell lymphoma. 27 However, p53 mutations does not seem to have any prognostic value in patients from the IPI H-I and H risk groups.
In the present study, we found that many patients with aggressive lymphoma had elevated pretreatment sFas levels. The sFas level was associated with the response to treatment, and patients with a low pretreatment sFas level often achieved CR. In contrast, a high pretreatment sFas level was associated with poor survival among our unselected patients with aggressive NHL given the COP-BLAM regimen. A high sFas level was particularly associated with a poor performance status and a high Ann Arbor stage.
The sFas level was slightly higher in bulky than in nonbulky lymphoma, but the difference was not significant. Consequently, sFas seems to be associated with tumor dissemination rather than tumor burden. The prognosis of T cell lymphoma was worse than that of B cell lymphoma, but there was no significant difference of the sFas level between them, indicating that factors other than sFas were involved in determining the prognosis. Munker et al 28 reported that the sCD95 level was higher in patients with low-and intermediate-grade NHL than in normal controls (P Ͻ 0.01), and that stratifying patients based on a cut-off value of 75 U/ml had no impact on progression coupled with the high incidence of recurrence considered to account for the comparable progression-free survival rates.
The association of overall and DFS with the serum sFas level was assessed according to IPI risk category. Among the 89 patients in the L and L-I risk groups, the serum sFas level was 10 ng/ml or higher in 15. The overall survival rate of these 15 patients was significantly lower than that of the others, but there was no significant difference in DFS between the two groups. The serum sFas level was 10 ng/ml or higher in 19 of the 42 patients from the H-I and H risk group. Both overall and DFS rates were significantly lower for these 19 patients than for the others.
According to Shipp et al, 7 the 5-year survival rate for the IPI L risk group was 73% after treatment with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), whereas the rate for the L-I risk group was 51%. The rates for the H-I and H risk groups were only 43% and 26%, respectively. 7 Therefore, they recommended CHOP as standard therapy for the L and L-I risk groups, but this regimen was not necessarily regarded as adequate for the IPI H-I and H groups. Accordingly, further investigation is necessary to develop strategies for the treatment of patients in these risk groups. Clinical studies have been conducted on high-dose chemotherapy administered in combination with peripheral blood stem cell transplantation (PBSCT), particularly in young patients, and it has been reported that such therapy was effective. 29, 30 Among patients in the H-I and H risk groups, however, some do not relapse even after administration of CHOP or COP-BLAM alone. This raises the problem of whether all these patients actually need high-dose induction therapy. The present study showed that a serum sFas level of 10 ng/ml or higher may predict a poor prognosis for overall and DFS. With respect to overall survival, the duration was decreased in patients from both the L + L-I and H-I + H risk groups when the serum sFas level was 10 ng/ml or higher. Even when the serum sFas level was elevated, DFS was not significantly worse in the L + L-I risk group. However, the DFS was significantly poorer when the serum sFas level exceeded 10 ng/ml in the H-I + H risk group.
Based on these findings, if the serum sFas level exceeds 10 ng/ml in the H-I + H risk group, high-dose chemotherapy in combination with PBSCT may be indicated, because the prognosis is significantly worse.
We performed multivariate analysis using sFas levels and the prognostic factors used to calculate the IPI in relation to the overall survival and DFS. These analyses showed that a high serum sFas level was an independent prognostic factor for both overall survival and DFS (Table 3) .
Consequently, if the sFas is used to estimate the outcome in new patients, more appropriate treatment for NHL may be selected.
